Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables
Guided Therapeutics (OTCQB: GTHP) has received full payment for an order from Indonesia consisting of four LuViva Advanced Cervical Scan devices and 1,200 single-use cervical guides. The equipment will be delivered in Q1 2025 to the government healthcare system in Sulawesi, an island with over 20 million inhabitants.
The LuViva systems will be used for early detection of cervical cancer, which is one of the most common female cancers in Indonesia. The technology is particularly suitable for the Indonesian healthcare system as it provides immediate results without requiring laboratory infrastructure. The company expects additional orders in the following year.
Guided Therapeutics (OTCQB: GTHP) ha ricevuto il pagamento completo per un ordine proveniente dall'Indonesia, composto da quattro dispositivi LuViva Advanced Cervical Scan e 1.200 guide cervicali monouso. L'attrezzatura sarà consegnata nel primo trimestre del 2025 al sistema sanitario pubblico di Sulawesi, un'isola con oltre 20 milioni di abitanti.
I sistemi LuViva saranno utilizzati per la diagnosi precoce del cancro cervicale, uno dei tumori femminili più comuni in Indonesia. La tecnologia è particolarmente adatta per il sistema sanitario indonesiano, in quanto fornisce risultati immediati senza la necessità di un'infrastruttura di laboratorio. La società si aspetta ordini aggiuntivi nell'anno successivo.
Guided Therapeutics (OTCQB: GTHP) ha recibido el pago completo por un pedido de Indonesia que consiste en cuatro dispositivos LuViva Advanced Cervical Scan y 1.200 guías cervicales desechables. El equipo será entregado en el primer trimestre de 2025 al sistema de salud pública en Sulawesi, una isla con más de 20 millones de habitantes.
Los sistemas LuViva se utilizarán para la detección temprana del cáncer de cuello uterino, que es uno de los tipos de cáncer femenino más comunes en Indonesia. La tecnología es especialmente adecuada para el sistema de salud indonesio, ya que proporciona resultados inmediatos sin requerir infraestructura de laboratorio. La compañía espera recibir pedidos adicionales en el año siguiente.
가이드 치료법(OTCQB: GTHP)은 인도네시아에서 주문한 네 개의 루비바 첨단 자궁경부 스캔 장치와 1,200개의 일회용 자궁경부 가이드에 대한 전액 결제를 받았습니다. 이 장비는 2025년 1분기에 수마트라 섬의 공공 의료 시스템에 제공될 예정이며, 이 섬에는 2천만 명 이상이 거주합니다.
루비바 시스템은 인도네시아에서 여성 암 중 가장 흔한 자궁경부암의 조기 발견을 위해 사용될 것입니다. 이 기술은 실험실 인프라 없이 즉각적인 결과를 제공하기 때문에 인도네시아 의료 시스템에 특히 적합합니다. 회사는 다음 해에 추가 주문이 있을 것으로 기대하고 있습니다.
Guided Therapeutics (OTCQB: GTHP) a reçu le paiement complet pour une commande provenant d'Indonésie, comprenant quatre dispositifs LuViva Advanced Cervical Scan et 1 200 guides cervicaux à usage unique. L'équipement sera livré au premier trimestre 2025 au système de santé public de Sulawesi, une île de plus de 20 millions d'habitants.
Les systèmes LuViva seront utilisés pour la détection précoce du cancer du col de l'utérus, qui est l'un des cancers féminins les plus courants en Indonésie. La technologie est particulièrement adaptée au système de santé indonésien car elle fournit des résultats immédiats sans nécessiter d'infrastructure de laboratoire. L'entreprise s'attend à d'autres commandes l'année suivante.
Guided Therapeutics (OTCQB: GTHP) hat die vollständige Zahlung für eine Bestellung aus Indonesien erhalten, die aus vier LuViva Advanced Cervical Scan-Geräten und 1.200 Einweg-Zervixführungen besteht. Die Ausrüstung wird im ersten Quartal 2025 an das öffentliche Gesundheitssystem auf Sulawesi, einer Insel mit über 20 Millionen Einwohnern, geliefert.
Die LuViva-Systeme werden zur frühzeitigen Erkennung von Gebärmutterhalskrebs eingesetzt, einer der häufigsten Krebsarten bei Frauen in Indonesien. Die Technologie ist besonders geeignet für das indonesische Gesundheitssystem, da sie sofortige Ergebnisse liefert, ohne dass eine Laborinfrastruktur erforderlich ist. Das Unternehmen erwartet im folgenden Jahr weitere Bestellungen.
- Secured full payment for 4 LuViva systems and 1,200 disposables
- Entry into Indonesian market with government healthcare system
- Potential for additional orders in the following year
- Market expansion into world's fourth most populous country
- Delivery delayed until Q1 2025
PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received full payment from its Indonesian distribution partner for four LuViva devices and 1,200 single-use cervical guides. Delivery of the systems is expected to occur in the first quarter of 2025. This initial shipment of LuViva devices for the government healthcare system in Sulawesi will be utilized to identify women with cervical cancer at its earliest stages, when it is most treatable.
Sulawesi is an island in the Indonesian archipelago with a population of over 20 million. Cervical cancer is one of the most common female cancers occurring in
“Because LuViva is a self-contained cervical cancer detection system that provides immediate results without the need for any laboratory infrastructure, it is well suited for the Indonesian healthcare system,” said Mark Faupel, Guided Therapeutics’ CEO. “We have been told to expect additional orders next year that will build upon this initial shipment.”
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the
Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical, or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and subsequent filings.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210621157/en/
Mark Faupel
Guided Therapeutics
770-242-8723
Source: Guided Therapeutics, Inc.
FAQ
What is the size of the recent Indonesian order for Guided Therapeutics (GTHP)?
When will Guided Therapeutics (GTHP) deliver the LuViva systems to Indonesia?
Where in Indonesia will the Guided Therapeutics (GTHP) LuViva systems be deployed?
Has Guided Therapeutics (GTHP) received payment for the Indonesian order?
